A TB Biorepository Dedicated to the Validation and Exploration of Biomarkers of TB Drug Effect
The Consortium for TB Biomarkers (CTB2) comprises the Global Alliance for TB Drug Development, the TB Trials Consortium, and the AIDS Clinical Trials Group. The CTB2 has created a collaborative biobank in order to accelerate the development of new drugs and treatments for tuberculosis by validating and exploring biomarkers of response to TB drug treatments. The biobank will ultimately house biospecimens from 1000 adult patients in long-term storage for use by the TB research community. Details about the biospecimens available for use in your research can be found here.
The CTB2 continues to offer biospecimens from the TB Biorepository to explore or validate TB biomarkers. Our application process is described here. We ask you to please contact us either by email at or by leaving a message at US +1 212-227-7540 for any questions or to initiate the first steps in the application process; we will follow up quickly to set a time to talk or discuss via email.
For details regarding the application process and deadlines, click here.
Click above to learn how, when, and where the samples were collected and prepared for long-term biostorage.